HBV Citations List: September 2024
Literature Citations
1. Rational Design, Synthesis, and Structure-Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836. Cole, A. G., S. G. Kultgen, N. Mani, K. Y. Fan, A. Ardzinski, K. Stever, B. D. Dorsey, E. F. Mesaros, E. P. Thi, I. Graves, S. Tang, T. O. Harasym, A. C. H. Lee, A. Olland, R. K. Suto, and M. J. Sofia. Journal of Medicinal Chemistry, 2024. 67(18): 16773-16795. PMID[39231272].
[PubMed]. HBV_09_2024.
2. Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses. Han, K., T. Dickens, G. McMullen, E. Swayze, M. McCaleb, G. Billioud, S. Wieland, S. Hood, M. Paff, C.F. Bennett and T.J. Kwoh. Clinical Pharmacology in Drug Development, 2022. 11(10):1191-1202. PMID[35971951]. PMCID[PMC9804925].
[PubMed]. HBV_09_2024.
3. Exploration of 1-(indolin-1-yl)-2-(thiazol-2-yl)ethan-1-one Derivatives as Novel Anti-HBV Agent with Potential TLR7-agonistic Effect. Li, S., L. Yang, Q. Xu, X. Li, J. Zhao, Z. Tan, X. Gu, and J. Qiu. European Journal Medicinal Chemistry, 2024. 275: 116575. PMID[38865744].
[PubMed]. HBV_09_2024.
4. Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators. Mesaros, E. F., A. G. Cole, S. G. Kultgen, N. Mani, K. Y. Fan, B. J. Dugan, A. Ardzinski, K. Stever, H. M. Micolochick Steuer, I. Graves, S. Tang, T. O. Harasym, A. M. Lam, E. P. Thi, B. D. Dorsey, and M. J. Sofia. ACS Medicinal Chemistry Letters, 2024. 15(9): 1627-1634. PMID[39291037] PMCID[PMC11403741].
[PubMed]. HBV_09_2024.
Patent Citations
5. Preparation of Fused Heterotetracyclic Antiviral Agents. Rafferty, S., S. Ghorai, N.T. Kenton, P. Xu, S. Bartlett, S. Mitchell, J.D. Panarese, and Y.S. Or. Patent. 2024. WO2024-US172422024182271: 130pp.
[Patent]. HBV_09_2024.